Yazar "Quek, R. G." için Tıp Fakültesi / Faculty of Medicine listeleme
-
Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
Gumus, M.; Kilickap, S.; Sezer, A.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G. (2023) -
Patient-Reported Outcomes (Pros) With First-Line (1L) Cemiplimab In Patients With Locally Advanced Non-Small Cell Lung Cancer (Lansclc): EMPOWER-Lung 1 Subpopulation
Bondarenko, I.; Sezer, A.; Kilickap, S.; Gumus, M.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G. (2022) -
Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G. (2022) -
Patient-Reported Outcomes with Cemiplimab Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer (Ansclc): Geographic Region Subgroups in EMPOWER-Lung 1
Ho, G. F.; Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G. (2022) -
Predictive Utility of Patient Reported Outcomes for Survival in 1st-Line Treated Patients with a NSCLC in EMPOWER-Lung 1 and 3
Gandara, D. R.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Guemues, M.; McIntyre, D. A.; He, X.; Yan, E.; Gullo, G.; Rietschel, P.; Quek, R. G. (2023)